1) Pfeffer MA, Swedberg K, Granger CB et al, CHARM Investigators and Committees:Effects of candesartan on mortality and morbidity in patients with chronic heart failure:the CHARM-Overall programme. Lancet 362:759-766, 2003
DATA UPDATE 循環系 第3版
商品紹介
世界各地で日々積み上げられている各領域の大規模臨床試験の最新結果を、臨床に携わるスタッフへコンパクトにまとめて解説。臨床の場で今、おさえておくべきメガトライアルを網羅。EBMの収集・理解・実践に最適な書。
目次
- DATA UPDATE 循環系 第3版
―目次―
■心臓
【心不全】
【不整脈】
【急性冠動脈疾患】
【慢性冠動脈疾患】
■高血圧
■脳血管障害
■高脂血症・動脈硬化
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
心臓【心不全】
P.13 掲載の参考文献
P.15 掲載の参考文献
2) The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group:Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441-1446, 1993
3) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
P.16 掲載の参考文献
P.18 掲載の参考文献
P.21 掲載の参考文献
1) Echt DS, Liebson PR, Mitchell LB et al:Mortality and morbidity in patients receiving encainide, flecainide, or placebo:the Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788, 1991
2) Doval HC, Nul DR, Grancelli HO et al:Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344:493-498, 1994
P.23 掲載の参考文献
1) MERIT-HF Study Group:Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
2) Gottlieb SS, Fisher ML, Kjekshus J et al:Toler-ability of β-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 105:1182-1188, 2002
3) Wikstrand J, Hjalmarson A, Waagstein F et al:Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure. J Am Co Cardiol 40:491-498, 2002
4) Hjalmarson A, Goldstein S, Fagerberg B et al:Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA 283:1295-1302, 2000
P.25 掲載の参考文献
1) Abraham WT, Fisher WG, Smith AL et al, MIRACLE Study Group:Multicenter InSync Randomized Clinical Evaluation:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002
2) Gregoratos G, Abrams J, Epstein AE et al:ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines:ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices:summary article:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 106:2145-2161, 2002
P.27 掲載の参考文献
1) Cazeau S, Leclercq C, Lavergne T et al:Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344:873-880, 2001
2) Leclercq C, Walker S, Linde C et al:Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 23:1780-1787, 2002
3) Linde C, Leclercq C, Rex S et al:Long-term benefits of biventricular pacing in congestive heart failure:Results from the multisite stimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 40:111-118, 2002
P.29 掲載の参考文献
1) Cuffe MS, Califf RM, Adams KF Jr et al:Shortterm intravenous milrinone for acute exacerbation of chronic heart failure:a randomized controlled trial. JAMA 287:1541-1547, 2002
P.31 掲載の参考文献
1) Nanas JN, Alexopoulos G, Anastasiou-Nana MI et al:Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril:a multicenter study. J Am Coll Cardiol 36:2090-2095, 2000
2) The CONSENSUS Trial Study Group:Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scan-dinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429-1435, 1987
5) Packer M, Poole-Wilson PA, Armstrong PW et al:Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:2312-2318, 1999
6) The NETWORK Investigators:Clinical outcome with enalapril in symptomatic chronic heart failure;a dose comparison. Eur Heart J 19:481-489, 1998
P.33 掲載の参考文献
1) Packer M, Califf RM, Konstam MA et al:Comparison of omapatrilat and enalapril in patients with chronic heart failure:the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106:920-926, 2002
P.35 掲載の参考文献
1) Kaluski E, Kobrin I, Zimlichman R et al:RITZ-5:randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema:a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41:204-210, 2003
P.37 掲載の参考文献
1) Cohn JN, Tognoni G:A randomized trial of the anigiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001
P.39 掲載の参考文献
1) Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF):Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial. JAMA 287:1531-1540, 2002
2) Colucci WS, Elkayam U, Horton DP et al:Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343:246-253, 2000
P.41 掲載の参考文献
P.43 掲載の参考文献
1) Weerasooriya R, Davis M, Powell A et al:The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 41:1697-1702, 2003
2) Kay GN, Ellenbogen KA, Giudici M et al:The Ablate and Pace Trial:a prospective study of catheter ablation of the AV conduction system and permanent pacemaker inplantation for treatment of atrial fibrillation. J Interv Card Electrophysiol 2:121-135, 1998
P.45 掲載の参考文献
1) Strickberger SA, Hummel JD, Bartlett TG et al:Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol 41:1707-1712, 2003
P.47 掲載の参考文献
1) Kuck KH, Cappato R, Siebels J et al:Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 102:748-754, 2000
P.49 掲載の参考文献
P.51 掲載の参考文献
1) Connolly SJ, Gent M, Roberts RS et al:Canadian implantable defibrillator study (CIDS):a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 101:1297-1302, 2000
P.53 掲載の参考文献
2) AFFIRM Investigators:Acomparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825-1833, 2002
P.55 掲載の参考文献
1) Connolly SJ, Kerr CR, Gent M et al:Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med 342:1385-1391, 2000
2) Skanes AC, Krahn AD, Yee R et al:Progression to chronic atrial fibrillation after pacing:the Canadian Trial of Physiologic Pacing. J Am Coll Cardiol 38:167-172, 2001
P.57 掲載の参考文献
1) Gregoratos G, Abrams J, Epstein AE et al:ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices:summary article:a report of the ACC/AHA Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) . Circulation 106:2145-2161, 2002
2) Wilkoff BL:Should all patients receive dual chamber pacing ICDs? The rationale for the DAVID trial. Curr Control Trials Cardiovasc Med 2:215-217, 2001
P.59 掲載の参考文献
1) Moss AJ, Hall WJ, Cannom DS et al:Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335:1933-1940, 1996
P.61 掲載の参考文献
1) Abraham WT, Fisher WG, Smith AL et al, MIRACLE Study Group:Multicenter InSync Randomized Clinical Evaluation:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002
P.64 掲載の参考文献
1) Abraham WT, Fisher WG, Smith AL et al:MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation:Cardiac resynchronization in chronic heart failure. N Engl J Med 346:1845-1853, 2002
P.67 掲載の参考文献
P.69 掲載の参考文献
P.71 掲載の参考文献
1) Van Gelder IC, Hagens VE, Bosker HA et al for the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group (RACE):A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347:1834-1840, 2002
P.73 掲載の参考文献
1) Montalescot G, Barragan P, Wittenberg O et al, ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up:Platelet glycoprotein II b/III a inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895-1903, 2001
P.76 掲載の参考文献
1) Batchelor WB, Mahaffey KW, Berger PB et al:A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting:the ATLAST trial. J Am Coll Cardiol 38:1608-1613, 2001
2) The EPISTENT Investigators:Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352:87-92, 1998
5) The CAPTURE Investigators:Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina:the CAPTURE Study[erratum published Lancet 359:744, 1997].Lancet 349:1429-1435, 1997
6) The IMPACT-II Investigators:Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention:IMPACT-II. Lancet 349:1422-1428, 1997
P.79 掲載の参考文献
2) Gurfinkel E, Bozovich G, Beck E et al:Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 20:121-127 1999
3) Muhlestein JB, Anderson JL, Carlquist JF et al:Randomized secondary prevention trial of azithromycin in patients with coronary artery disease:primary clinical results of the ACADEMIC study. Circulation 102:1755-1760, 2000
P.81 掲載の参考文献
1) The CAPRICORN Investigators:Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction:the CAPRICORN randomised trial. Lancet 357:1385-1390, 2001
P.83 掲載の参考文献
1) CAPTURE Investigators:Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable an-gina:the CAPTURE Study. Lancet 349:1429-1435, 1997
2) Hamm CW, Heeschen C, Goldmann B et al:Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c 7 E 3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 340:1623-1629, 1999, Erratum in:N Engl Med 341:548, 1999
P.85 掲載の参考文献
3) The PRISM-PLUS Study Investigators:Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction[published correction appears in N Engl J Med 339:415, 1998]. N Engl J Med 338:1488-1497, 1998
4) The RESTORE Investigators:Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453, 1997
5) Batchelor WB, Tolleson TR, Huang Y et al:Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes:The COMPARE trial. Circulation 106:1470-1476, 2002
P.87 掲載の参考文献
1) Bhatt DL, Lee BI, Casterella PJ et al:Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention:results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 41:20-25, 2003
3) Rao AK, Pratt C, Berke A et al:Thrombolysis in Myocardial Infarction (TIMI) trial-phase I:hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11, 1988
P.88 掲載の参考文献
1) Budaj A, Yusuf S, Mehta SR et al:Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106:1622-1626, 2002
2) Antman EM, Cohen M, Bernink PJ et al:The TIMI risk score for unstable angina/non-ST elevation MI:A method for prognostication and therapeutic decision making. JAMA 284:835-842, 2000
3) The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE):Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502, 2001
4) Mehta SR, Yusuf S, Peters RJ et al:Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention:the PCI-CURE study. Lancet 358:527-533, 2001
P.92 掲載の参考文献
1) Kober L, Bloch Thomsen PE, Molleer M et al:Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction:a randomised trial. Lancet 356:2052-2058, 2000
2) Echt DS, Liebson PR, Mitchell B et al and CAST investigators:Mortality and morbidity in patients receiving encainide, flecainaide, or placebo:The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788, 1991
P.95 掲載の参考文献
1) Antman EM, Louwerenburg HW, Baars HF et al:Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction:results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105:1642-1649, 2002
2) Topol EJ, GUSTO V Investigators:Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition:the GUSTO-V randomised trial. Lancet 357:1905-1914, 2001
3) Antman EM, Giugliano RP, Gibson CM et al:Abciximab facilitates the rate and extent of thrombolysis:results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99:2720-2732, 1999
P.97 掲載の参考文献
1) Zeymer U, Suryapanata H, Monassier JP et al:Evaluation of the safety and of the cardioprotective effects of eniporide, a specific sodium/hydrogen exchange inhibitor given as adjunctive therapy to reperfusion in patients with acute myocardial infarction:rationalc, design and protocol of the ESCAMI study. Heart study. 1:71-76, 2001
2) Zeymer U, Suryapranata H, Monassier JP et al:The Na+/H+Exchange Inhibitor Eniporide as an Adjunct to Early Reperfusion Therapy for Acute Myocardial Infarction. J Am Coll Cardiol 38:1644-1650, 2001
P.98 掲載の参考文献
1) O'Shea JC, Buller CE, Cantor WJ et al:Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 287:618-621, 2002
2) The ESPRIT Investigators:Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT):arandomized, placebo-controlled trial. Lancet 356:2037-2044, 2000
3) Topol EJ, Mark DB, Lincoff AM et al for the EPISTENT Investigators:Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting:results from a multicentre randomised trial. Lancet 354:2019-2024, 1999
P.100 掲載の参考文献
1) Goodman SG, Cohen M, Bigonzi F et al:Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. J Am Coll Cardiol 36:693-698, 2000
2) Cohen M, Demers C, Gurfinkel EP et al:Acomparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-452, 1997
3) Oler A, Whooley MA, Oler J et al:Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 276:811-815, 1996
P.104 掲載の参考文献
1) Moscucci M, Fox KA, Cannon CP et al:Predictors of major bleeding in acute coronary syndromes:the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24:1815-1823, 2003
2) Montalescot G, Van de Werf F, Gulba DC et al:Stenting and glycoprotein IIb/IIIa inhibition inpatients with acute myocardial infarction undergoing Percutaneous coronary intervention:findings from the global registry of acute coronary events (GRACE). Catheter Cardiovasc Interv 60:360-367, 2003
3) Fox KA, Goodman SG, Klein W et al:Management of acute coronary syndromes. Variations in practice and outcome;findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 23:1177-1189, 2002
4) Eagle KA, Goodman SG, Avezum A et al:Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction:findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359:373-377, 2002
5) Spencer FA, Santopinto JJ, Gone JM et al:Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes (The Global Registry of Acute Coronary Events [GRACE]).Am J Cardiol 90:1056-1061, 2002
6) Santopinto JJ, Fox KA, Goldberg RJ et al:Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes:findings from the global registry of acute coronary events (GRACE). Heart 89:1003-1008, 2003
7) Klein W, Kraxner W, Hodl R et al:Patterns of use of heparins in ACS. Correlates and hospital out-comes:the Global Registry of Acute Coronary Events (GRACE). Thromb Haemost 90:519-527, 2003
8) Steg PG, Goldberg RJ, Gore JM et al:Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90:358-363, 2002
9) GRACE Investigators:Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project:a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141:190-199, 2001
P.108 掲載の参考文献
1) Simoons ML, GUSTO IV-ACS Investigators:Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet 357:1915-1924, 2001
3) Ottervanger JP, Armstrong P, Barnathan ES et al, GUSTO IV-ACS Investigators:Long-term results after the glycoprotein II b/III a inhibitor abciximab in unstable angina:one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV-Acute Coronary Syndrome) Trial. Circulation 107:437-442, 2003
4) EPIC Investigators:Use of a monoclonal antibody directed against the platelet glycoprotein II b/III a receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994
5) EPILOG Investigators:Platelet glycoprotein II b/ III a receptor blockade and low-dose heparin during Percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997
P.111 掲載の参考文献
1) Lincoff AM, Califf RM, Van de Werf F et al:Global Use of Strategies To Open Coronary Arteries Investigators (GUSTO):Mortality at 1 year with combination platelet glycoprotein II b/III ainhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction:GUSTO V randomized trial. JAMA 288:2130-2135, 2002
2) Topol EJ, GUSTO V Investigators Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition:the GUSTO V randomised trial. Lancet 357:1905-1914, 2001
P.113 掲載の参考文献
1) Ross AM, Molhoek P, Lundergan C et al:Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin:Second Trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104:648-652, 2001
P.114 掲載の参考文献
1) Goodman SG, Fitchett D, Armstrong PW et al:Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glyco-protein IIb/IIIa inhibitor eptifibatide. Circulation 107:238-244, 2003
2) Cohen M, Demers C, Gurfinkel EP et al:Acomparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-452, 1997
P.117 掲載の参考文献
1) Brener SJ, Zeymer U, Adgey AAJ et al:Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. J Am Coll Cardiol 39:377-386, 2002
2) Ohman EM, Kleiman NS, Gacioch G et al:Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 95:846-854, 1997
P.119 掲載の参考文献
1) Schwartz GG, Olsson AG, Ezekowitz MD et al:Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial. JAMA 285:1711-1718, 2001
P.121 掲載の参考文献
1) Eikelboom JW, Anand SS, Mehta SR et al:Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation:Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. Circulation 103:643-650, 2001
2) Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators:Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischemia without ST elevation:a randomized trial. Lancet 353:429-438, 1999
P.123 掲載の参考文献
1) Dickstein K, Kjekshus J:Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction:the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 83:477-481, 1999
2) Dickstein K, Kjekshus J, OPTIMAAL Trial Steering Committee and Investigators:Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan:Comparison of baseline data, initial course, and management:losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol 87:766-771, A7, 2001
3) Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group:Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360:752-760, 2002
P.125 掲載の参考文献
1) Weaver WD, Reisman MA, Griffin JJ et al:Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1):a randomised trial. Lancet 355:2199-2203, 2000
2) The F. R. O. S. T. Study Group:The French Randomised Optimal Stenting Trial:a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. J Am Coll Cardol 36:404-409, 2000
P.127 掲載の参考文献
1) Cannon CP, McCabe CH, Wilcox RG et al for the OPUS-TIMI 16 Investigators:Oral glycoprotein II b/III a inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) Trial. Circulation 102:149-156, 2000
2) EPIC Investigators:Use of a monoclonal antibody directed against the platelet glycoprotein II b/III a receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994
3) EPILOG Investigators:Platelet glycoprotein II b/ III a receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696, 1997
P.129 掲載の参考文献
1) Moliterno DJ, for the PARAGON B International Steering Committee:Patient-specific dosing of IIb/ III a antagonists during acute coronary syndromes:rationale and design of the PARAGON B study. Am Heart J 139:563-566, 2000
2) The Platelet II b/III a Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON)-B Investigators:Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 105:316-321, 2002
3) Boersma E, Harrington RA, Moliterno DJ et al:Platelet glycoprotein II b/III a inhibitors in acute coronary syndromes:a meta-analysis of all major randomized clinical trials. Lancet 359:189-198, 2002
P.131 掲載の参考文献
2) Vuillemenot A, Schiele F, Meneveau N et al:Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent a pilot study in the setting of coronary angioplasty. Thromb Heamost 81:214-220, 1999
3) Ross AM, Molhoek P, Lundergan C et al:Randomized comparison of enoxaparin, a low-molecular weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin:second trial of Heparin and Aspirin Reperfusion Therapy (HART II) . Circulation 104:648-652, 2001
P.135 掲載の参考文献
1) Widimsk'y P, Groch L, Zelizko M et al:Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE Study. Euar Heart J 21:823-831, 2000
3) Widimsky P, Budesinsky T, Vorac D et al:Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 24:94-104, 2003
P.136 掲載の参考文献
1) Luepker RV, Raczynski JM, Osganian S et al:Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease:The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA 284:60-67, 2000
2) Brodie BR, Stuckey TD, Wall TC et al:Importance of time to reperfusion for 30-days and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 32:1312-1319, 1998
3) Raczynski JM, Finnegan JR, Zapka JG et al:REACT theory-based intervention to reduce treatment-seeking delay for acute MI. Am J Prev Med 16:325-334, 1999
4) Goff DC Jr, Sellers DE, McGovern PG et al:Knowledge of heart attacks symptoms in a population survey in the United States:The REACT Trial. Arch Intern Med 158:2329-2338, 1998
P.140 掲載の参考文献
1) Fox KA, Poole-Wilson PA, Henderson RA et al, for the Randomized Intervention Trial of unstable angina (RITA) investigators:Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction;the British Heart Foundation RITA 3 randomised trial. Lancet 360:743-751, 2002
P.143 掲載の参考文献
1) Gibler WB, Hoekstra JW, Weaver WD et al:A randomized trial of the effects of early cardiac serum marker availability on reperfusion therapy in patients with acute myocardial infarction:the serial markers, acute myocardial infarction and rapid treatment trial (SMARTT). J Am Coll Cardiol 36:1500-1506, 2000
P.145 掲載の参考文献
1) Stone AF, Mendall MA, Kaski JC et al:Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes:South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 106:1219-1223, 2002
P.147 掲載の参考文献
1) Le May MR, Labinaz M, Davies RF et al:Stenting versus thrombolysis in acute myocardial infarction trial (STAT).J Am Coll Cardiol 37:985-991, 2001
P.149 掲載の参考文献
1) Grines CL, Cox DA, Stone GW et al:Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 341:1949-1956, 1999
P.150 掲載の参考文献
1) Schomig A, Kastrati A, Dirschinger J et al:Coronay stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 343:385-391, 2000
P.153 掲載の参考文献
2) Schomig A, Kastrati A, Dirschinger J et al:Coronay stenting Plus Platelet glycoprotein II b/IIIa blockade compared with tissue plasminogen activatior in acute myocardial infarction. N Engl J Med 343:385-391, 2000
3) Antman EM, Giugliano RP, Gibson CM et al:Abciximab facilitates the rate and extent of thrombolysis:results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99:2720-2732, 1999
P.155 掲載の参考文献
1) The SYMPHONY Investigators:Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes:a randomized trial. Lancet 355:337-345, 2000
P.158 掲載の参考文献
2) Morrow DA, Cannon CP, Rifai N et al:Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction:results from a randomized trial. JAMA 286:2405-2412, 2001
3) Sabatine MS, Morrow DA, de Lemos JA et al:Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes:simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circualation 105:1760-1763, 2002
4) Wong GC, Morrow DA, Murphy S et al:Elevations in troponin T and I are associated with abnormal tissue level perfusion:a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 106:202-207, 2002
5) de Lemos JA, Morrow DA, Gibson CM et al:The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11 B and TACTICS-TIMI 18 studies. J Am Coll Cardiol 40:238-244, 2002
6) Kleiman NS, Lakkis N, Cannon CP et al:Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 40:1044-50, 2002
7) Mahoney EM, Jurkovitz CT, Chu et al:Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 288:1851-1858, 2002
8) Glaser R, Herrmann HC, Murphy SA et al:Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 288:3124-3129, 2002
9) Morrow DA, de Lemos JA, Sabatine MS et al:Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction:B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Collcardiol 41:1264-1272, 2003
P.161 掲載の参考文献
1) Topol EJ, Moliterno DJ, Herrmann HC et al:Comparison of two platelet glycoprotein II b/III a inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344:1888-1894, 2001
2) Moliterno DJ, Topol EJ for the TARGET International Steering Committee:A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement:rationale and design of the TARGET study. Am Heart J 140:722-726, 2000
P.163 掲載の参考文献
2) The TRACE Study Group:The Trandolapril Cardiac Evaluation (TRACE) Study:rationale, design, and baseline characteristics of the screened population. Am J Cardiol 73:44 C-50 C, 1994
3) Kober L, Trop-Pedersen C:Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) study. A J Cardiol 76:1-5, 1995
4) Torp-Pedersen C, Kober L:Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 354:9-12, 1999
P.165 掲載の参考文献
1) Pfeffer MA, McMurray JJV, Velazquez EJ et al:Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003
3) The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators:Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828, 1993
5) Dickstein K, Kjekshus J for the OPTIMAAL Study Group:Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction:the OPTIMAAL randomised trial.Lancet 360:752-760, 2002
6) Dahlof B, Devereux RB, Kieldsen SE et al for the LIFE study group:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
P.167 掲載の参考文献
1) Serruys PW, Foley DP, Suttorp MJ et al:A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions:final results of the additional value of NIR stents for treatment of long coronary lesions (ADVANCE) study. J Am Coll Cardiol 39:393-399, 2002
2) Colombo A, De Gregorio J, Moussa I et al:Intravascular ultrasound-guided percutaneous transluminal coronary angiography with provisional spot stenting for treatment of long coronary lesions. J Am Coll Cardiol 38:1427-1433, 2001
3) Schofer J, Schluter M, Gershlick AH et al:Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093-1099, 2003
P.169 掲載の参考文献
1) Serruys PW, Unger F, Sousa JE et al for the Arterial Revascularization Therapies Study Group:Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344:1117-1124, 2001
2) Abizaid A, Costa MA, Centemero M et al:Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients:insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 104:533-538, 2001
3) Costa MA, Carere RG, Lichtenstein SV et al:Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 104:2689-2693, 2001
4) van den Brand MJ, Rensing BJ, Morel MA et al:The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 39:559-564, 2002
P.171 掲載の参考文献
1) Park SJ, Shim WH, Ho DS et al:Apaclitaxel-eluting stent for the prevention of coronary res-tenosis. N Engl J Med 348:1537-1545, 2003
3) Morice MC, Serruys PW, Sousa JE et al:A radomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002
P.172 掲載の参考文献
1) Morrison DA, Sethi G, Sacks J et al:Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia:AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 40:1951-1954, 2002
2) Eagle KA, Guyton RA, Davidoff R et al:ACC/ AHA guidelines for coronary artery bypass graft surgery:a report of the American College of Cardiology/American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 34:1262-1347, 1999
P.175 掲載の参考文献
1) Schiele F, Meneveau N, Gilard M et al:Intravascular ultrasound-guided balloon angioplasty compared with stent:immediate and 6-month results of the multicenter, randomized Balloon Equivalent to Stent Study (BEST). Circulation 107:545-551, 2003
P.177 掲載の参考文献
1) Carrie D, Khalife K, Citron B et al:Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. Am J Cardiol 87:693-698, 2001
2) Loubeyre C, Morice MC, Lefevre T et al:A randomised comparison of direct stenting with conventional stent implantation in selected patients With Acute Myocardial Infarction. J Am Coll Cardol 39:15-21, 2002
P.179 掲載の参考文献
2) Ascione R, Caputo M, Calori G et al:Predictors of atrial fibrillation after conventional and beating heart coronary surgery:aprospective, randomised study. Circulation 102:1530-1535, 2000
3) Ascione R, Lloyd CT, Underwood MJ et al:Economic outcome of off-pump coronary artery bypass surgery:a prospective randomized study. Ann Thorac Surg 68:2237-2242, 1999
4) van Dijk D, Nierich AP, Jansen EW et al:Early outcome after off-pump versus on-pump coronary bypass surgery:results from a randomized study. Circulation 104:1761-1766, 2001
P.181 掲載の参考文献
1) Jorgensen B, Simonsen S, Endresen K et al:Restenosis and clinical outcome in patients treated with amlodipine after angioplasty:results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 35:592-599, 2000
P.183 掲載の参考文献
1) Bertrand ME, Rupprecht HJ, Urban P et al:Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting:the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102:624-629, 2000
P.185 掲載の参考文献
1) Poldermans D, Boersma E, Bax JJ et al:The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Engl J Med 341:1789-1794, 1999
2) Boersma E, Poldermans D, Bax JJ et al:Predictors of cardiac events after major vascular surgery. Role of clinical characteristics, dobutamine echocardiography, and β-blocker therapy. JAMA 285:1865-1873, 2001
P.187 掲載の参考文献
1) The EPILOG investigators:Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med 336:1689-1696, 1997
P.189 掲載の参考文献
1) Stone G, Rogers C, Hermiller J et al:Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation 108:548-553, 2003
P.191 掲載の参考文献
2) Waksman R, Ajani AE, Pinnow E et al:Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma radiation therapy for in-stent restenosis:Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 106:776-778, 2002
P.193 掲載の参考文献
1) Neumann F, Kastrati A, Miethke T et al:Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3):arandomised, double-blind, placebo-controlled trial [comment]. Lancet 357:2085-2089, 2001
P.195 掲載の参考文献
1) Kastrati A, Schomig A, Dirschinger J et al:A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. Circulation 102:2593-2598, 2000
2) Koning R, Eltchaninoff H, Commeau P et al:Stent placement compared with balloon angioplasty for small coronary arteries:in-hospital and 6-month clinical and angiographic results. Circulation 104:1604-1608, 2001
3) Moer R, Myreng Y, Molstad P et al:Stenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. J Am Coll Cardiol 38:1598-1603, 2001
P.197 掲載の参考文献
1) Kastrati A, Mehilli J, Dirschinger J et al:Intracoronary stenting and angiographic results:strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103:2816-2821, 2001
2) Hausleiter J, Kastrati A, Mehilli J et al:Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol 40:882-889, 2002
P.199 掲載の参考文献
1) Shaw LW:Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in patients after a myocardial infarction. The National Exercise and Heart Disease Project. Am J Cardiol 48:39-46, 1981
2) Dorn J, Naughton J, Imamura D et al:Results of a multicenter randomized clinical trial of exercise and long-term survival in myocardial infarction patients:the National Exercise and Heart Disease Project (NEHDP). Circulation 100:1764-1769, 1999
3) Oldridge NB, Guyatt GH, Fischer ME et al:Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 260:945-950, 1988
P.201 掲載の参考文献
1) Borst C, Jansen EW, Tulleken CA et al:Coronary artery bypass grafting without cardiopulmonary bypass and without interruption of native coronary flow using a novel anastomosis site restraining device ("Octopus"). J Am Coll Cardio l 27:1356-1364, 1996
2) Nathoe HM, van Dijk D, Jansen EW et al:A comparison of On-pump and Off-pump coronary bypass surgery in low-risk patients. N Engl J Med 348:394-402, 2003
3) Cleveland JC Jr, Shroyer AL, Chen AY et al:Off-pump coronary artery bypass grafting decreases risk-adjusted mortality and morbidity. Ann Thorac Surg 72:1282-1288, 2001
P.202 掲載の参考文献
1) Mudra H, di Mario C, de Jaegere P et al:Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation 104:1343-1349, 2001
2) de Jaegere P, Mudra H, Figulla H et al:Intravascular ultrasound-guided optimized stent deployment:Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur Heart J 19:1214-1223, 1998
P.204 掲載の参考文献
1) Holmes DR, Savage M, LaBlanche JM et al:Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial. Curculation 106:1243-1250, 2002
2) Tamai H, Katoh O, Suzuki T et al:Impact of tranilast on restenosis after coronary angioplasty:Tranilast Restenosis Following Angioplasty Trial (TREAT). Am Heart J 138:968-975, 1999
3) Tamai H, for the TREAT Group:Inhibitory effect of tranilast on restenosis after percutaneous transluminal coronary angioplasty (PTCA):a phase III multicenter randomized double blind placebocontrolled trial. J Clin Ther Med 12:65-85, 1996
P.207 掲載の参考文献
1) Byington RP, Miller ME, Herrington D et al:Rationale, design and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Traial (PREVENT). Am J Cardiol 80:1087-1090, 1997
2) Pitt B, Byington RP, Furberg CD et al:Effects of amlodipine on the progression of atherosclerosis and the occurrence of clinical Events. Circulation 102:1503-1510, 2000
P.209 掲載の参考文献
1) Blankenberg S, Luc G, Ducimetiere P et al:Inter-leukin-18 and the risk of coronary heart disease in European men:The prospective epidemiological study of myocardial infarction (PRIME). Circulation 108:2453-2459, 2003
2) The PRIME study group:The PRIME study:classical risk factors do not explain the severalfold differences in risk of coronary heart disease between France and Northern Ireland. QJM 91:667-676, 1998
P.211 掲載の参考文献
2) Moses JW, Leon MB, Popma JJ et al:Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323, 2003
3) Regar E, Serruys PW, Bode C et al:Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL):sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 106:1949-1956, 2002
P.213 掲載の参考文献
1) Lincoff AM, Bittl JA, Harrington RA et al:Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during Percutaneous coronary intervention. JAMA 289:853-863, 2003
2) Weitz JI, Hudoba M, Massel D et al:Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III independent inhibitors. J Clin Invest 86:385-391, 1990
3) Lefkovits J, Topol EJ:Direct thrombin inhibitors in cardiovascular medicine. Circulation 90:1522-1536, 1994
P.215 掲載の参考文献
P.217 掲載の参考文献
2) Teirstein PS, Massullo V, Jani S et al:Three-year clinical and angiographic follow-up after intracoronary radiation:results of a randomized clinical trial. Circulation 101:360-365, 2000
P.219 掲載の参考文献
1) Schnyder G, Roffi M, Flammer Y et al:Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention:the Swiss Heart study:A randomized controlled trial. JAMA 288:973-979, 2002
2) Schnyder G, Roffi M, Pin R et al:Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593-1600, 2001
3) Welch GN, Loscalzo J:Homocysteine and ather-othrombosis. N Engl J Med 338:1042-1050, 1998
P.221 掲載の参考文献
1) The TIME Investigators:Trial of invasive versus medical therapy in the elderly (TIME):study protocol and patient outline. Heart Drug 1:144-147, 2001
4) Hulley S, Grady D, Bush T et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613, 1998
5) Hochman JS, Sleeper LA, Webb JG et al:Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Oc-cluded Coronaries for Cardiogenic Shock. N Engl J Med 341:625-634, 1999
P.223 掲載の参考文献
1) Waksman R, Bhargava B, White L et al:Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis. Circulation 101:1895-1898, 2000
高血圧
P.227 掲載の参考文献
1) Agodoa LY, Appel L, Bakris GL et al:Effect of ramipril vs amlodipine on renal outcomes in hyper-tensive nephrosclerosis:a randomized controlled trial. JAMA 285:2719-2728, 2001
2) Wright JT Jr, Bakris G, Greene T et al:Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease:result from the AASK trial. JAMA 288:2421-2431, 2002
P.229 掲載の参考文献
2) Peterson JC, Klahr S, Massry SG et al:Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
3) Bakris GL, Williams M, Dworkin L et al:Preserving renal function in adults with hypertension and diabetes:Aconsensus approach. Am J Kidney Dis 36:646-661, 2000
4) Viberti G, Wheeldon NM for the MARVAL Study Investigators:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 106:672-678, 2002
P.232 掲載の参考文献
1) ALLHAT Officiers and Coordinators for the ALLHAT Collaborative Research Group:Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone:the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 283:1967-1975, 2000
2) ALLHAT Officiers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Anti:hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
P.233 掲載の参考文献
1) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Diuretic versus α-blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hympertension 42:239-246, 2003
2) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967-1975, 2000
P.235 掲載の参考文献
1) Wing LMH, Reid CM, Ryan P et al:A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. (the Second Australian National Blood Pressure Study) N Engl J Med 348:583-592, 2003
2) Dahlof B, Devereux RB, Kjeldsen SE et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hyper-tension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
3) ALLHAT officers and coordinators for the ALLHAT collaborative research group:Major out-comes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
P.237 掲載の参考文献
1) 黒川清:高血圧を伴う腎疾患の長期治療試験結果概要. Ther Res 22:275-282, 2001
2) 黒川清:高血圧を伴う腎疾患の長期治療試験結果-ATRD-. 新薬と治療 52:31-33, 2002
P.239 掲載の参考文献
1) Mogensen CE, Neldam S, Tikkanen I et al:Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes:the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321:1440-1444, 2000
2) Nakao N, Yoshimura A, Morita H et al:Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):arandomised controlled trial. Lancet 361:117-124, 2003
P.241 掲載の参考文献
2) Neal B, MacMahon S, Chapman N:Blood Pressure Lowering Treatment Trialist's Collaboration:Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs:results of prospectively designed over-views of randomised trials. Lancet 356:1955-1964, 2000
P.243 掲載の参考文献
1) Nakao N, Yoshimura A, Morita H et al:Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):a randomized controlled trial. Lancet 361:117-124, 2003
P.245 掲載の参考文献
1) Appel LJ, Moore TJ, Obarzanek E et al:Aclinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336:1117-1124, 1997
P.246 掲載の参考文献
1) Lievre M, Marre M, Chatellier G et al:The non-insulin-dependent diabetes, hypertension, microal-buminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study:design, organization, and patient recruitment. Control Clin Trials 21:383-396, 2000
2) Vaur L, Gueret P, Lievre M et al:Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria:observations from DIABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events ant Ramipril) study. Diabetes Care 26:855-860, 2003
P.248 掲載の参考文献
1) van Jaarsveld BC, Krijnen P, Pieterman H et al:The effect of ballon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 342:1007-1014, 2000
P.251 掲載の参考文献
1) Zanchetti A, Bond MG, Hennig M et al:Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis:principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 106:2422-2427, 2002
P.253 掲載の参考文献
1) Wilhelmsen L, Berglund G, Elmfeldt D et al:Beta-blockers versus diuretics in hypertensive man:main results from the HAPPHY trial. J Hypertens 5:561-572, 1987
2) Wikstrand J, Warnold I, Tuomilehto J et al:Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 17:579-588, 1991
P.255 掲載の参考文献
2) Staessen JA, Wang JG, Thijs L:Cardiovascular protection and blood pressure reduction:ameta-analysis. Lancet 358:1305-1315, 2001
P.257 掲載の参考文献
1) Lewis EJ, Hunsicker LG, Clarke WR et al:Reno-protective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
P.259 掲載の参考文献
2) Brown MJ, Castaigne A, Ruilope LM et al:IN-SIGHT:international nifedipine GITS study intervention as a goal in hypertension treatment. J Hum Hypertens 10:S 157-S 160, 1996
P.260 掲載の参考文献
1) Mancia G, Brown M, Castaigne A et al:Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 41:431-436, 2003
P.261 掲載の参考文献
1) Pepine CJ, Handberg-Thurmond E, Marks RG et al:Rationale and design of the international verapamil SR/trandolapril study (INVEST):an Internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol 32:1228-1237, 1998
P.263 掲載の参考文献
P.265 掲載の参考文献
1) Yui Y, Sumiyoshi T, Kodama K et al:Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease:the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens 27:181-191, 2004
P.267 掲載の参考文献
1) Baba S:The J-MIND Study Group:Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 54:191-201, 2001
P.269 掲載の参考文献
2) Blood Pressure Lowering Treatment Trialists' Collaboration:Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs:results of prospectively designed over-views of randomised trials. Lancet 355:1955-1964, 2000
P.271 掲載の参考文献
1) Kjeldsen SE, Dahlof B, Devereux RB et al:Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losarttan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 288:1491-1498, 2002
P.272 掲載の参考文献
1) Lindholm LH, Ibsen H, Dahlof B et al:Cardiovas cular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:1004-1010, 2002
P.275 掲載の参考文献
1) Viberti G, Wheeldon NM:MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect. Circulation 106:672-678, 2002
P.276 掲載の参考文献
1) Heart Outcomes Prevention Evaluation Study Investigators:Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253-259, 2000
P.279 掲載の参考文献
1) Hansson L, Hedner T, Lund-Johansen P et al:Randornised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension:the Nordic Diltiazem (NORDIL) study. Lancet 356:359-365, 2000
P.281 掲載の参考文献
1) Ogihara T:Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens 13:461-467, 2000
P.283 掲載の参考文献
1) Schrader J, Luders S, Zuchner C et al:Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study):a randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment. J Hum Hypertens 14:435-440, 2000
P.285 掲載の参考文献
1) Dahlof B, Pennert K, Hansson L:Reversal of left ventricular hypertrophy in hypertensive patients:a metaanalysis of 109 treatment studies. Am Hypertens 5:95-110, 1992
2) Gottidiener JS, Reda DJ, Massie BM et al:Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension:comparison of six antihypertensive agents Circulation 95:2007-2014, 1997
3) Devereux RB, Palmieri V, Sharpe N et al:Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based anti-hypertensive treatment regimens on left ventricular hypertrophy and diastoleic filling in hypertension. The prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 104:1248-1254, 2001
P.286 掲載の参考文献
2) Fransen M, Anderson C, Chalmers J et al:PROGRESS:Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6,105 patients with cerebrovascular disease:a randomized controlled trial. Stroke 34:2333-2338, 2003
3) Tzourio C, Anderson C, Chapman N et al:PROGRESS Collaborative Group:Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163:1069-1075, 2003
P.288 掲載の参考文献
1) The PROGRESS Collaborative Group:Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163:1069-1075, 2003
P.291 掲載の参考文献
P.293 掲載の参考文献
1) Lithell H, Hansson L, Skoog I et al:The Study on Cognition and Prognosis in the Elderly (SCOPE):principal results of a randomized double-blind intervention trial. J Hypertens 21:875-886, 2003
2) Leys D:Neurological protection provided by candesartan:reviewing the latest study results. Curr Med Res Opin 19:445-448, 2003
P.294 掲載の参考文献
1) Malacco E, Gnemmi AE, Romagnoli A et al:Systolic hypertension in the elderly:long-term lacidipine treatment. Objective, protocol, and organization. SHELL Study Group. J Cardiovasc Pharmacol 23 (suppl 5):S 62-S 66, 1994
2) Malacco E, Mancia G, Rappelli A et al:Treatment of isolated systolic hypertension:the SHELL study results. Blood Press 12:160-167, 2003
P.297 掲載の参考文献
1) Hansson L, Lindholm LH, Ekbom T et al:Randomised trial of old and new antihypertensive drugs in elderly patients:cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354:1751-1756, 1999
P.298 掲載の参考文献
1) Lindholm LH, Anderson H, Ekbom T et al:Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hyper tension-2:a 5-year, prospective, randomised, controlled trial. Lancet 358:539-544, 2001
P.299 掲載の参考文献
1) Lindholm LH, Hansson L, Ekbom T et al:Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients:results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 18:1671-1675, 2000
2) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-721, 1998
P.301 掲載の参考文献
1) Celis H, Staessen JA, Buntinx F et al:Antihypertensive treatment based on home or office blood pressure measurement:protocol of the randomized controlled THOP trial. Blood. Press Monit 3 (suppl 1):S 29-S35, 1998
2) Hond ED, Celis H, Fagard R et al:Self-measured versus ambulatory blood pressure in the diagnosis of hypertension. J Hypertens 21:717-722, 2003
3) Staessen JA, Elly Den Hond, Hilde Celis et al:Antihypertensive treatment based on blood pressure measurement at home or in the physician's office. JAMA 291:955-964, 2004
P.303 掲載の参考文献
1) http://www.dtu.ox.ac.uk/index.html?maindoc=/ukpds/
P.306 掲載の参考文献
1) Julius S, Kjeldsen SE, Brunner H et al:VALUE Trial:Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 16:544-548, 2003
2) Julius S, Kjeldsen SE, Weber M et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial. Lancet 363:2022-2031, 2004
P.309 掲載の参考文献
1) Rosei EA, Dal Palu C, Leonetti G et al on behalf of the VHAS Investigators:Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hympertens 15:1337-1344, 1997
2) Zanchetti A, Rosei EA, Dal Palu C et al on behalf of the VHAS Investigators:The Verapamil in Hypertension and Atherosclerosis Study (VHAS):results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens 16:1667-1676, 1998
P.310 掲載の参考文献
1) The BENEDICT Group:The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT):design and baseline characteristics. Controlled Clin Trials 24:442-461, 2003
P.311 掲載の参考文献
1) 荻原俊男:本邦での大規模臨床試験-(CASE-J) . 日本臨牀 60:2045-2049, 2002
P.312 掲載の参考文献
1) Brown MJ, Hopper RV, Dickerson C:Coronary prevention and hypertension research clinic. J Hum Hypertens 7:100, 1993
P.313 掲載の参考文献
1) Ohkubo T, Imai Y, Tsuji I et al:Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement:apopulation-based observation in Ohasama, Japan. J Hypertens 16:971-975, 1998
2) Fujiwara T, Nishimura T, Ohkuko T et al:Rationale and design of HOMED-BP Study:hypertension objective treatment based on measurement by electrical devices of blood pressure study. Blood Press Monit 7:77-82, 2002
P.314 掲載の参考文献
1) Hansson L, Hedner T, Dahlof B:Prospective randomized open blinded end-point evaluation (PROBE) Study:a novel design for intervention trials. Blood Press 1:113-119, 1992
2) Stamler J, Stamler R, Neaton JD:Blood pressure, systolic and diastolic, and cardiovascular risks. Arch Intern Med 153:598-615, 1993
3) Franklin SS, Gustin W 4th, Wong ND et al:Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circzalation 96:308-315, 1997
4) Perry HM, Davis BR, Price TR et al:Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA 284:465-471, 2000
P.315 掲載の参考文献
1) Callif RM, Holman R:People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance. J Am Coll Cardiol 41 (suppl A):530 A-531 A, 2003
P.316 掲載の参考文献
2) Unger T:The ongoing telmisartan alone and in combination with ramipril global endopoint trial program. Am J Cardiol 91 (10 A):28 G-34 G, 2003
P.317 掲載の参考文献
1) Stumpe KO, Ludwig M, Heagerty AM et al:Vascular wall thickness in hypertension:the Perindopril Regression of Vascular Thickening European Community Trial:PROTECT. Am J Cardiol 76:50 E-54 E, 1995
脳血管障害
P.321 掲載の参考文献
1) Schrader J, Rothemeyer M, Luders S et al:Hypertension and stroke-rationale behind the ACCESS trial. Basic Res Cardiol 93 (Suppl. 2):69-78, 1998
P.323 掲載の参考文献
P.325 掲載の参考文献
1) CAVATAS investigators:Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS):a randomized trial. Lancet 357:1729-1737, 2001
P.327 掲載の参考文献
1) Wahlgren NG, Ranasinha KW, Rosolacci T et al:Clomethiazole acute stroke study (CLASS). Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients. Strolke 30:21-28, 1999
2) Bamford J, Sandercock P, Dennis M et al:Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337:1521-1526, 1991
3) Wahlgren NG, Diez-Tejedor E, Teitelbaum J et al:Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke 31:82-85, 2000
4) Lyden P, Jacoby M, Schim J et al:The clomethiazole acute stroke study in tissue-type plasminogen activator-treated stroke (CLASS-T) . Final results. Neurology 57:1199-1205, 2001
P.329 掲載の参考文献
1) Hacke W, Kaste M, Fieschi C et al:Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) . JAMA 274:1017-1025, 1995
2) Larrue V, von Kummer R, del Zoppo G et al:Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 28:957-960, 1997
3) Fiorelli M, Bastianello S, von Kummer R et al:Hemorrhagic transformation within 36 hours of a cerebral infarct. Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 30:2280-2284, 1999
4) Manefle C, Larrue V, von Kummer R et al:Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. Stroke 30:769-772, 1999
5) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med 333:1581-1587, 1995
6) Hacke W, Bluhmki E, Steiner T et al:Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set. Post hoc analysis of ECASS I. Strolee 29:2073-2075, 1998
P.331 掲載の参考文献
1) Hacke W, Kaste M, Fieschi C et al:Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) . Lancet 352:1245-1251, 1998
2) Larrue V, von Kummer R, Muller A et al:Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II) . Stroke 32:438-441, 2001
3) Berger C, Fiorelli M, Steiner T et al:Hemorrhagic transformation of ischemic brain tissue. Asymptomatic or symptomatic? Stroke 32:1330-1335, 2001
P.333 掲載の参考文献
1) European Carotid Surgery Trialists:Collaborative Group:Randomized trial of endarterectomy for recently symptomatic carotid stenosis:final results of MRC European Carotid Surgery Trial (ECST). Lancet 351:1379-1387, 1998
P.336 掲載の参考文献
1) ESPS Group:European Stroke Prevention Study. Strolee 21:1122-1130, 1990
2) Diener HC, Cunha L, Forbes C et al:European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13, 1996
3) Antithrombotic Trailists Collaboration:Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMI 324:71-86, 2002
4) Antiplatelet Trailists' Collaboration:Collaborative overview of randomised trials of antiplatelet therapy-I:Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994
P.339 掲載の参考文献
1) International Stroke Trial Collaborative Group:The International Stroke Trial (IST):a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 349:1569-1581, 1997
2) CAST (Chinese Acute Stroke Trial) Collaborative Group:CAST;Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641-1649, 1997
P.341 掲載の参考文献
P.343 掲載の参考文献
1) The Multicenter Acute Stroke Tria1-Europe Study Group:Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 335:145-150, 1996
2) Multicentre Acute Stroke Trial. Italy (MAST-1) Group:Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 346:1509-1514, 1995
3) Donnan GA, Davis SM, Chambers BR et al:Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 276:961-966, 1996
4) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995
P.345 掲載の参考文献
3) Alamowitch S, Eliasziw M, Algra A et al:Risk, causes, and prevention of ischaemic stroke in elderly patients with symptomatic internal-carotid-artery stenosis. Lancet 357:1154-1160, 2001
P.349 掲載の参考文献
1) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group:Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995
2) The NINDS t-PA Stroke Study Group:Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Strofee 28:2109-2118, 1997
3) NINDS;The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group:Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 31:2912-2919, 2000
5) Grotta JC, Chiu D, Lu M et al:Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 30:1528-1553, 1999
6) Broderick JP, Lu M, Kothari R et al:Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 31:2335-2341, 2000
7) Lyden PD, Lu M, Levine SR et al:A modified National Institutes of Health Stroke Scale for use in stroke clinical trials:preliminary reliability and validity. Stroke 32:1310-1317, 2001
P.351 掲載の参考文献
P.353 掲載の参考文献
1) The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group:A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857-865, 1997
2) Antiplatelet Trialists' Collaboration:Collaborative overview of randomized trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106, 1994
3) Antithrombotic Trialists' Collaboration:Collaborative meta-analysis of randomized trilas of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324:71-86, 2002
4) 篠原幸人, 吉本高志, 福内靖男ほか:脳卒中合同ガイドライン委員会:脳卒中治療ガイドライン2004, 協和企画発行, 2004
6) Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group:Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343:499-503, 1994
7) Mohr Jp, Thompson JL, Lazar RM et al:A comparison of Warfarin and aspirin for prevention of recurrent ischemic stroke. N Engl J Med 345:1444-1451, 2001
P.357 掲載の参考文献
1) The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators:Low molecular weight heparinoid ORG 10172 (danaparoid), and outcome after acute ischemic stroke:a randomized controlled trial. JAMA 279:1265-1272, 1998
2) International Stroke Trial Collaborative Group, The International Stroke Trial (IST):Arandomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569-1581, 1997
3) CAST (Chinese Acute Stroke Trial) Collaborative Group:CAST:randomised placebo-controlled trial of early aspirin use in 20000 patients with acute ischaemic stroke. Lancet 349:1641-1649, 1997
4) 田崎義昭, 小林祥泰, 東儀英夫ほか:脳血栓症に対する抗トロンビン薬MD-805の臨床的有用性. プラセボを対照とした多施設二重盲検群間比較試験. 医学のあゆみ 161:887-907, 1992
P.359 掲載の参考文献
2) Hankey GJ:Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial;Is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke? Stroke 33:1723-1726, 2002
P.361 掲載の参考文献
1) De Schryver EL, on behalf of the European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group:Design of ESPRIT;An international randomized trial for secondary pre-vention after non-disabling cerebral ischaemia of arterial origin. Cerebrovasc Dis 10:147-150, 2000
2) De Schryver EL, on behalf of the European/Aus-tralian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) Group:ESPRIT;protocol change. Cerebrovasc Dis 11:286, 2001
高脂血症・動脈硬化
P.365 掲載の参考文献
1) Egan DA, Garg R, Wilt TJ et al:Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol 83:569-575, 1999
3) Garg R, Elam MB, Crouse JR III et al:Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. Am Heart J 140:792-803, 2000
4) Elam MB, Hunninghake DB, Davis KB et al:Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease:the ADMIT study:a randomized trial. JAMA 284:1263-1270, 2000
6) Brown BG, Zhao XQ, Chait A et al:Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001
P.369 掲載の参考文献
1) Downs JR, Clearfield M, Weis S et al:Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels;results of AFCAPS/TexCAPS. JAMA 279:1615-1622, 1998
2) Gotto AM Jr, Whitney E, Stein EA et al:Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101:477-484, 2000
4) The Kyushu Lipid Intervention Study Group:A coronary primary intervention study of Japanese men:study design, implementation and baseline data. J Atheroscler Thromb 3:95-104, 1996
5) The Kyushu Lipid Intervention Study Group:Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolmia:the Kyushu Lipid Intervention Study. J Atheroscler Thromb 7:110-121, 2000
P.371 掲載の参考文献
1) The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT-LLT). JAMA 288:2998-3007, 2002
2) Pasternak RC:The ALLHAT lipid lowering trialless is less. JAMA 288:3042-3044, 2002
P.373 掲載の参考文献
1) Taylor AJ, Kent SM, Flaherty PJ et al:ARBITER:Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol:arandomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106:2055-2060, 2002
2) Shah PK:Low-density lipoprotein lowering and atherosclerosis progression:does more mean less? Circulation 106:2039-2040, 2002
P.375 掲載の参考文献
1) Smilde TJ, Trip MD, Wollersheim H et al:Rationale, design and baseline characteristics of a clinical trial comparing the effect of robust vs conventional cholesterol lowering and intima media thickness in patients with familial hypercholesterolemia:the atorvastatin vs simvastatin on atherosclerosis progression (ASAP) study. Clin Drug Invest 20:67-79, 2000
2) Smilde TJ, van Wissen S, Wollersheim H et al:Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP):a prospective, randomised, double-blind trial. Lancet 357:577-581, 2001
P.377 掲載の参考文献
1) Sever PS, Dahlof B, Poulter NR et al:Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. J Hypertens 19:1139-1147, 2001
2) Sever PS, Dahlof B, Poulter NR et al:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomized controlled trial. Lancet 361:1149-1158, 2003
P.379 掲載の参考文献
1) Hedblad B, Wilkstrand J, Janzon L et al:Lowdose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness:Main results from the β-blocker cholesterol-lowering asymptomatic plaque study. Circulation 103:1721-1726, 2001
2) Hjalmarson A, Goldstein S, Fagerberg B et al:Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure:the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA 283:1295-1302, 2000
P.381 掲載の参考文献
1) Tanne D, Benderly M, Goldbourt U et al:Aprospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med 111:457-463, 2001
2) The BIP study group:Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21-27, 2000
3) Adams HP Jr, Bendixen BH, Kappelle LJ et al:Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical tria. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35-41, 1993
P.383 掲載の参考文献
1) The ENCORE Investigators:Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease;the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 107:422-428, 2003
P.385 掲載の参考文献
1) 武谷雄二, 大内尉義 (編):改訂高齢女性の健康増進のためのホルモン補充療法ガイドライン. メディカルレビュー社, 東京, 2004
2) Hulley S, Grady D, Bush T et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
P.387 掲載の参考文献
1) Hulley S, Grady D, Bush T et al:Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613, 1998
2) Grady D, Herrington D, Bittner V et al:Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 288:49-57, 2002
3) 佐久間一郎, 北畠顕:第100回日本内科学会講演会シンポジウム. 1. ホルモンと長寿. 2) 女性の閉経と心血管疾患. 日本内科学会雑誌92:1690-1694, 2003
P.389 掲載の参考文献
1) Serruys PW, Feyter P, Macaya C et al:Lescol Intervention Prevention Study (LIPS) Investigators:Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention:a randomized controlled trial. JAMA 287:3215-3222, 2002
2) Herd JA, Ballantyne CM, Farmer JA et al:Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study[LCAS]). Am J Cardiol 80:278-286, 1997
P.391 掲載の参考文献
1) Simpson RJ Jr:Placing PRINCE in perspective. JAMA 286:91-93, 2001
2) Albert MA, Danielson E, Rifai N et al:Effect of statin therapy on C-reactive protein levels:the pravastatin inflammation/CRP evaluation (PRINCE):a randomized trial and cohort study. JAMA 286:64-70, 2001
P.393 掲載の参考文献
2) Robins SJ, Collins D, Wittes JT et al:Relation of gemfibrozil treatment and lipid levels with major coronary events:VA-HIT:a randomized controlled trial. JAMA 285:1585-1591, 2001
3) Robins SJ:Targeting low high-density lipoprotein cholesterol for therapy:lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 88 (suppl):19 N-23 N, 2001
P.396 掲載の参考文献
1) http://www.nhlbi.nih.gov/whi
2) http://www.nhlbi.nih.gov/whi/estro_alone.htm
3) http://www.nhlbi.nih.gov/whi/estro_pro.htm
4) The Women's Health Initiative Steering Committee:Effects of conjugated equine estrogen in postmenopausal women with hysterectomy the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004
5) http://www.nhlbi.nih.gov/new/press/04-04-13.htm
6) http://www.wfubmc.edu/whims/
7) http://www.fda.gov/cder/drug/infopage/estrogens_progestins/default.htm
8) Writing Group for the Women's Health Initiative Investigators:Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
P.399 掲載の参考文献
1) Merz CN, Kelsey SF, Pepine CJ et al:The Women's Ischemia Syndrome Evaluation (WISE) study:protocol design, methodology and feasibility report. J Am Coll Cardiol 33:1453-1461, 1999
2) Sharaf BL, Pepine CJ, Kerensky RA et al:Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation[WISE]Study Angiographic Core Laboratory). Am J Cardiol 87:937-941, 2001
3) Lin L, Lewis JF, Kerensky RA et al:Exercise treadmill testing in women with suspected myocardial ischemia;new findings using ACIP protocol;NHLBI Women's Ischemia Syndrome Evaluation (WISE). J Am Coll Cardiol 33:327 A, 1999
4) Lewis JF, Lin L, McGorray S et al:Dobutamine stress echocardiography in women with chest pain. Pilot phase data from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). J Am Coll Cardiol 33:1462-1468, 1999
5) Reis SE, Holubkov R, Conrad Smith AJ et al:Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease:results from the NHLBI WISE study. Am Heart J 141:735-741, 2001
6) Bairey Merz CN, Johnson BD, Sharaf BL et al:Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women:a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 41:413-419, 2003
7) Bairey Merz CN, Olson MB, Johnson BD et al:Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women:the Women's Ischemia Syndrome Evaluation (WISE). Am J Med 113:723-727, 2002
8) Rutledge T, Reis SE, Olson M et al:History of anxiety disorders is associated with a decreased likelihood of angiographic coronary artery disease in women with chest pain:the WISE study. J Am Coll Cardiol 37:780-785, 2001
最近チェックした商品履歴
Loading...
販売価格 990 円（税込）
心臓【心不全】
-
心臓【心不全】P.11
-
CHARMP.12
-
COMETP.14
-
COPERNICUSP.16
高血圧
-
高血圧P.225
-
AASKP.226
-
ABCD-2VP.228
-
ALLHATP.230
脳血管障害
-
脳血管障害P.319
-
ACCESSP.320
-
ACEP.322
-
CAVATASP.324
高脂血症・動脈硬化
-
高脂血症・動脈硬化P.363
-
ADMITP.364
-
AFCAPS / TexCAPSP.366
-
ALLHAT-LLTP.370